Damora Therapeutics, Inc.

DMRA

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001800315

None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $260.5M
Warnings	dilution, thin data not computable: degenerate inputs, fortress balance sheet
Inputs computable	5 of 13
Graded from	filings received through Mar 19, 2026 247 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$23.16 2026-11-20; market equity $1.4B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 19, 2026

We are a biopharmaceutical company developing therapies for the treatment of hematologic disorders. In our previously announced Asset Acquisition (as defined below), we bolstered our pipeline with the addition of three product candidates designed to treat myeloproliferative neoplasms ("MPNs"), a group of related, chronic disorders of the bone marrow. Our lead product candidate, DMR-001, targets mutant forms of the calcium binding protein calreticulin ("CALR"), which are collectively known as mutCALR. We have exercised our Option to license exclusive worldwide development and commercialization rights to DMR-001 from Paragon Therapeutics, Inc.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 2.4						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						
Accruals ratio	(146.3%)	(6.7%)		2.4	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 12.4						
Altman Z double-prime	7.04	0.31		14.3	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
one or more required annual facts are missing						
Current ratio	12.98x	2.68x		10.4	781	2025-12-31
Growth and financing, sleeve percentile 52.9						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 2						
Reinvestment rate	not computable	33.9%				
NOPAT must exceed $100,000						
Asset growth, three years	52.7%	3.2%		7.3	663	2025-12-31
Net share issuance, one year	4,460.3%	1.6%		98.6	626	2026-03-17

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 4460.3%
Thin data	5 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	190.7%	(1.7%)	97
Distance from 52-week high	(32.0%)	(33.0%)	51
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(3.0%)	0.6%	37
Book value to price	0.34	0.29	55
Sales to price	not computable	0.38	
Composite equity issuance, five years	411.5%	13.5%	98
Relative strength against the sector, log excess return	0.90	(0.19)	97
Twelve-month failure probability, CHS model	1.35%	0.06%	84

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$349.7M
Operating cash flow, four quarters	-$59.1M
Months of runway	71.0
Days since last periodic filing	17 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$10.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$209.8M	2025-12-31	2026-03-19	10-K	26-115922
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$6.7M	2025-12-31	2026-03-19	10-K	26-115922
3	assets	us-gaap:Assets	$260.5M	2025-12-31	2026-03-19	10-K	26-115922
4	assets	us-gaap:Assets	$17.1M	2024-12-31	2026-03-19	10-K	26-115922
5	current assets	us-gaap:AssetsCurrent	$260.4M	2025-12-31	2026-03-19	10-K	26-115922
6	current liabilities	us-gaap:LiabilitiesCurrent	$20.1M	2025-12-31	2026-03-19	10-K	26-115922
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$487.4M	2025-12-31	2026-03-19	10-K	26-115922
8	operating income	us-gaap:OperatingIncomeLoss	-$210.9M	2025-12-31	2026-03-19	10-K	26-115922
9	book equity	us-gaap:StockholdersEquity	$240.4M	2025-12-31	2026-03-19	10-K	26-115922
10	liabilities	us-gaap:Liabilities	$20.1M	2025-12-31	2026-03-19	10-K	26-115922
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$196,000	2022-12-31	2024-03-08	10-K	24-028610
12	depreciation amortization	us-gaap:Depreciation	$42,000	2022-12-31	2024-03-08	10-K	24-028610
13	operating income	us-gaap:OperatingIncomeLoss	-$61.2M	2022-12-31	2024-03-08	10-K	24-028610
14	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$61.6M	2022-12-31	2024-03-08	10-K	24-028610
15	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2022-12-31	2024-03-08	10-K	24-028610
16	current assets	us-gaap:AssetsCurrent	$63.9M	2022-12-31	2024-03-08	10-K	24-028610
17	current liabilities	us-gaap:LiabilitiesCurrent	$11.1M	2022-12-31	2024-03-08	10-K	24-028610
18	current assets	us-gaap:AssetsCurrent	$110.1M	2021-12-31	2023-03-09	10-K	23-006807
19	current liabilities	us-gaap:LiabilitiesCurrent	$4.5M	2021-12-31	2023-03-09	10-K	23-006807
20	assets	us-gaap:Assets	$38.2M	2023-12-31	2025-03-19	10-K	25-041981
21	assets	us-gaap:Assets	$73.2M	2022-12-31	2024-03-08	10-K	24-028610
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	60,303,212	2026-03-17	2026-03-19	10-K	26-115922
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,322,359	2025-03-14	2025-03-19	10-K	25-041981

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.